Universal Ibogaine Inc. is a life science company listed on OTC with the ticker symbol $IBOGF. In the last 52 weeks the range of the lower and upper price is $0.0258-$0.1143.
The Company newly reported that its common shares, coined as "JC4", have been accepted for trade on the Frankfurt Stock Exchange, or Boerse Frankfurt. In Canada, UI will keep trading on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the stock symbol IBOGF.
Our mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery. While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
$IBO stock ticker to Universal Ibogaine a company that provides ibogaine addiction treatment to patients tormented from opioid addiction in Canada is currently trading swiftly at $0.03734 with an evident hike.
Blue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
It gives UI great pleasure to announce that Nick Karos, CEO, will speak at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond. On June 27, 2022, a hybrid online and offline event will take place. "H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance...
GHCL IS A MICROCAP STOCK, ,MCAP of 5500 cr ROCE:-26% ROE:-24% Fundamentally Strong stock setup:- ENTRY(day timeframe) - only if we spot healthy green with good volume candle at our retest leval entry should be taken above at the highh of that healthy candle stoploss - only if the candle closes below our stoploss level views...
UI is developing an advanced holistic addiction treatment protocol, at its Kelburn Recovery Centre, that when combined with the planned ibogaine detox methodology is expected to transform the way we treat addiction and dramatically promote the welfare of families affected by addiction.
The UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
$IBO has been elastic through the ebbs and flows of the market and have always maintained a tight toe hold in the Canadian venture exchange, its consistency to this day is what intrigues investors globally, the shares are trading at $0.05 with no such recorded loss
The volume of $IBOGF is increasing day by day. In the last 30 days the average volume of $IBOGF has been recorded to be $4.42K.
Universal Ibogaine Inc. is a life science company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical trial.
Universal Ibogaine Inc. a life science company listed on OTC with the ticker symbol $IBOGF has been seen with a higher day range difference. The day range is $0.0367-$0.0385.
Universal Ibogaine is working with Health Canada to undertake a planned clinical trial in Canada to demonstrate the safety and efficacy of the Ibogaine treatment protocol for opioid use disorder.
At the Kelburn Clinic, UI is developing a cutting-edge holistic addiction treatment protocol that, when combined with the anticipated ibogaine detox programme, will transform the way we treat addiction and dramatically enhance the lives of individuals and families plagued by addiction.
$IBOGF is trading swiftly in the market and observing a plenty of investor activities, the shares are trading live on OTC at $0.095 with an amazing 178% profit on value per share.
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.